Preclinical models show that CSF-1R inhibition reduces TAM infiltration, disrupts M2 programming, and downregulates the CXCL12/CXCR4 axis, an important pathway for tumor cell survival and chemoresistance. This evidence concerns the gene CSF1R and neoplasm.